Cargando…

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers

The use of generic drugs has been increasing. However, studies of the safety of generic cisplatin (CDDP) for the treatment of head and neck cancer (HNC) have not been reported. This study investigated the treatment completion rates and incidence of CDDP-related adverse events in patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimada, Rie, Tsukahara, Kiyoaki, Takase, Soichiro, Okamoto, Isaku, Sato, Hiroki, Katsube, Yasuaki, Maruyama, Ryo, Shimizu, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802811/ https://www.ncbi.nlm.nih.gov/pubmed/29434483 http://dx.doi.org/10.1177/1179670717749231

Ejemplares similares

Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma
por: Sato, Hiroki, et al.
Publicado: (2018)

Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise
por: Ito, Tatsuya, et al.
Publicado: (2021)

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma
por: Okamoto, Isaku, et al.
Publicado: (2022)

Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy
por: Okamoto, Isaku, et al.
Publicado: (2022)

A Case of Oropharyngeal Carcinoma with an Oblique Neck that Benefited from Transoral Robotic Surgery
por: Yamakura, Tatsuya, et al.
Publicado: (2023)

Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy
por: Oike, Takahiro, et al.
Publicado: (2013)

Photoimmunotherapy for Managing Recurrent Laryngeal Cancer Cervical Lesions: A Case Report
por: Okamoto, Isaku, et al.
Publicado: (2022)

A Case of Septicemia due to Nonocclusive Mesenteric Ischemia Occurring in Induction Chemotherapy
por: Tanaka, Hideki, et al.
Publicado: (2018)

Joint Use of Skull Base Surgery in a Case of Pediatric Parotid Gland Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2014)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Two Cases of Small Cell Cancer of the Maxillary Sinus Treated with Cisplatin plus Irinotecan and Radiotherapy
por: Tsukahara, Kiyoaki, et al.
Publicado: (2013)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
por: Ochi, Nobuaki, et al.
Publicado: (2014)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Preoperative Evaluation of Substernal Goiter by Computed Tomography in the Extended Neck Position
por: Yano, Teruhisa, et al.
Publicado: (2021)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Postoperative Complications and Swallowing Function after Jejunal and Skin Flap Reconstruction for Hypopharyngeal Carcinoma—A Multicenter Retrospective Study
por: Tokashiki, Kunihiko, et al.
Publicado: (2022)

Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706)
por: Tahara, Makoto, et al.
Publicado: (2015)

Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study
por: Kubota, Akira, et al.
Publicado: (2018)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Prospective Randomized Trial on Postoperative Administration of Diet Containing Eicosapentaenoic Acid, Docosahexaenoic Acid, Gamma-linolenic Acid, and Antioxidants in Head and Neck Cancer Surgery Patients with Free-flap Reconstruction
por: Tsukahara, Kiyoaki, et al.
Publicado: (2014)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
por: Bagri, Puneet Kumar, et al.
Publicado: (2014)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma
por: Hirai, Hideaki, et al.
Publicado: (2020)

A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI)
por: Hida, Naoya, et al.
Publicado: (2012)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

Chemoradiotherapy for Head and Neck Cancer
por: D’Onofrio, Ida, et al.
Publicado: (2023)

Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution
por: Benvenga, Salvatore, et al.
Publicado: (2019)

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
por: Kim, J G, et al.
Publicado: (2005)

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
por: Hoek, Jantien, et al.
Publicado: (2016)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hanemaaijer, Saskia H., et al.
Publicado: (2020)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)

Regulatory filing strategy for generic mesalazine modified release formulations
por: Gupta, Sandeep K.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gbrm2h4upr5urr8ut5esdja4f7